There is currently no text in this page. You can search for this page title in other pages, or search the related logs, but you do not have permission to create this page.
Category:C07K16/28
Jump to navigation
Jump to search
Subcategories
This category has the following 61 subcategories, out of 61 total.
A
B
C
D
E
G
H
J
K
L
M
N
O
P
R
S
T
W
Y
Z
Pages in category "C07K16/28"
The following 130 pages are in this category, out of 130 total.
1
- 17415589. Compositions and Methods for Enhancing Body Weight and Lean Muscle Mass Using Antagonists Against Leptin Receptor, GDF8 and Activin A simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 17767856. ONCOLYTIC VIRUSES THAT EXPRESS MULTI-SPECIFIC IMMUNE CELL ENGAGERS simplified abstract (Arizona Board of Regents on Behalf of Arizona State University)
- 17769171. COMPOSITIONS AND METHODS FOR DETECTING PLXDC1 AND PLXCD2 IN HUMAN TISSUES simplified abstract (The Regents of the University of California)
- 18018660. COMPOSITIONS INCLUDING SOLID FORMS OF POLYPEPTIDES AND RELATED METHODS (MASSACHUSETTS INSTITUTE OF TECHNOLOGY)
- 18193062. CANCER TREATMENT COMBINATIONS simplified abstract (The Regents of the University of California)
- 18234229. METHODS FOR SENSITIZING CANCER CELLS TO T CELL-MEDIATED KILLING BY MODULATING MOLECULAR PATHWAYS simplified abstract (DANA-FARBER CANCER INSTITUTE, INC.)
- 18260377. ANTI-CD72 NANOBODIES FOR IMMUNOTHERAPY simplified abstract (The Regents of the University of California)
- 18267257. T CELL RECRUITING POLYPEPTIDES BASED ON TCR ALPHA/BETA REACTIVITY simplified abstract (SANOFI)
- 18269803. NK CELL ENGAGER MOLECULES AND METHODS OF USE simplified abstract (REGENTS OF THE UNIVERSITY OF MINNESOTA)
- 18274145. TREATMENT OF NEUROENDOCRINE CANCERS (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
- 18274979. IMMUNE RECEPTORS WITH SYNTHETIC CO-STIMULATORY DOMAINS simplified abstract (The Regents of the University of California)
- 18277914. SINGLE DOMAIN ANTIBODY AGAINST CD47 AND USE THEREOF simplified abstract (SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION)
- 18277926. SINGLE DOMAIN ANTIBODY AGAINST PD-L1 AND USE THEREOF simplified abstract (SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION)
- 18294767. METHODS TO ENHANCE EFFICACY OF COMBINED TARGETING OF IMMUNE CHECKPOINT AND MAPK PATHWAYS (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
- 18295036. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING simplified abstract (Wisconsin Alumni Research Foundation)
- 18302738. METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY simplified abstract (The Regents of the University of California)
- 18359569. LDL RECEPTOR-DIRECTED BISPECIFIC BINDING AGENT-LIGAND FUSIONS FOR THE DEGRADATION OF TARGET PROTEINS simplified abstract (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
- 18384176. INHIBITING ANTI-ENPP1 ANTIBODIES simplified abstract (The Regents of the University of California)
- 18398367. POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-6 AND TNF ALPHA simplified abstract (SANOFI)
- 18400943. RADIOLABELED MET BINDING PROTEINS FOR IMMUNO-PET IMAGING simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18412280. FGFR3 BINDING MOLECULES AND METHODS OF USE THEREOF simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18438746. METHODS OF TREATING CANCER PAIN BY ADMINISTERING A PD-1 INHIBITOR simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18458657. LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY simplified abstract (Massachusetts Institute of Technology)
- 18480038. ANTIBODY FUSION PROTEIN AND RELATED COMPOSITIONS FOR TARGETING CANCER simplified abstract (Arizona Board of Regents on Behalf of Arizona State University)
- 18517327. BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF USE simplified abstract (Genentech, Inc.)
- 18546081. MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN ROR1 simplified abstract (The Regents of the University of California)
- 18550914. METHODS FOR TREATING GYNECOLOGIC CANCER USING COMBINATION THERAPY WITH ANTI-MUC16 x CD3 MULTISPECIFIC ANTIBODIES AND VEGF INHIBITORS simplified abstract (The General Hospital Corporation)
- 18552131. HYBRID RECEPTORS WITH MULTIPLE TRANSCRIPTIONAL REGULATORS simplified abstract (The Regents of the University of California)
- 18552141. SYNTHETIC INTERMEMBRANE PROTEOLYSIS RECEPTORS FOR CUSTOM ANTIGEN-INDUCED TRANSCRIPTIONAL REGULATION simplified abstract (The Regents of the University of California)
- 18560003. STRUCTURE BASED ISOLATION OF PMHC-RESTRICTED ANTIBODIES simplified abstract (THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY)
- 18561331. METHODS OF TREATMENT OF CANCER PATIENTS HAVING ALTERED SETD2 BIOMARKER WITH A PD-1 ANTAGONIST simplified abstract (Merck Sharp & Dohme LLC)
- 18568218. ANTIBODIES THAT STIMULATE NK CELL-MEDIATED CYTOTOXICITY simplified abstract (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
- 18579425. HUMAN IPSC-DERIVED MACROPHAGE simplified abstract (The Regents of the University of California)
- 18594234. ANTI-CXCR5 ANTIBODIES AND COMPOSITIONS AND USES THEREOF simplified abstract (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
- 18597797. ADAM6 MICE simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18620748. Use of CD2/5/7 Knock-Out Anti-CD2/5/7 Chimeric Antigen Receptor T cells Against T Cell Lymphomas and Leukemias simplified abstract (The Trustees of the University of Pennsylvania)
- 18627108. WNT SIGNALING AGONIST MOLECULES (University of Washington)
- 18636947. CELL-BASED ASSAY FOR DETECTING ANTl-CD3 HOMODIMERS simplified abstract (GENENTECH, INC.)
- 18637124. ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18643312. BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD19 and CD20 simplified abstract (The Regents of the University of California)
- 18648209. PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES simplified abstract (Genentech, Inc.)
- 18656957. HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION simplified abstract (Hoffmann-La Roche Inc.)
- 18680465. ANTIBODY MOLECULES TO PD-1 AND USES THEREOF (President and Fellows of Harvard College)
- 18680910. ANTI-NPR1 ANTIBODIES AND USES THEREOF simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18681787. METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA simplified abstract (HOFFMANN-LA ROCHE INC.)
- 18705653. ENGINEERED FC VARIANTS (Novartis AG)
- 18728813. Listeria Variants and Methods of Use Thereof (The Regents of the University of California)
- 18732998. BISPECIFIC ANTI-HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE simplified abstract (Hoffmann-La Roche Inc.)
- 18737782. Anti-Trkb Monoclonal Antibodies And Methods Of Use simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18737807. COMBINATION THERAPY FOR TREATMENT OF CORONARY ARTERY DISEASE (The Board of Trustees of the Leland Stanford Junior University)
- 18750233. ENHANCED CHIMERIC ANTIGEN RECEPTORS AND USE THEREOF simplified abstract (Board of Regents, The University of Texas System)
- 18784586. NEUTRALIZING ANTIBODIES TO THE ALPHA V BETA 8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY (The Regents of the University of California)
- 18792232. CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
- 18883719. COMPOSITIONS AND METHODS FOR TARGETED IMMUNOMODULATORY ANTIBODIES AND FUSION PROTEINS (The Johns Hopkins University)
- 18907274. COMPOSITIONS AND METHODS USEFUL IN PROMOTING MILK PRODUCTION (The Regents of the University of California)
- 18951146. BISPECIFIC HUMANIZED SINGLE DOMAIN ANTIBODY TO PD-L1 AND CD47, AND USE THEREOF (SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION)
- 18956269. METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES (Genentech, Inc.)
- 18956408. LABELED PROBE AND METHODS OF USE (The Board of Trustees of the Leland Stanford Junior University)
- 18956412. COMPOSITIONS AND METHODS FOR WILLIAMS SYNDROME (WS) THERAPY (MASSACHUSETTS INSTITUTE OF TECHNOLOGY)
2
- 20240010707. De-immunized Factor VIII Molecule and Pharmaceutical Compositions Comprising the Same simplified abstract (Biotest AG)
- 20240010980. NATURAL KILLER CELLS WITH ENHANCED ACTIVITY simplified abstract (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
- 20240025963. DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES simplified abstract (2seventy bio, Inc.)
- 20240052039. PROTEIN, POLYNUCLEOTIDE, VECTOR, HOST CELL, COMPOSITION, METHOD FOR TREATING AN ILLNESS, IN-VITRO METHOD FOR PREDICTING MULTIPLE SCLEROSIS, AND USE OF A PROTEIN OR COMPOSITION simplified abstract (Fundação Oswaldo Cruz)
- 20240052392. CELL CULTURE COMPOSITIONS AND METHODS FOR POLYPEPTIDE PRODUCTION simplified abstract (GENENTECH, INC.)
A
B
- Beijing Gene MiNK Biotechnology CO.LTD (20250018035). METHOD FOR EFFICIENTLY INFECTING HUMAN NATURAL KILLER CELLS AND OTHER IMMUNE CELLS WITH PSEUDOVIRUS
- Biotechnology patent applications on 14th Feb 2025
- Biotechnology patent applications on 23rd Aug 2024
- Biotechnology patent applications on August 22nd, 2024
- Biotechnology patent applications on February 13th, 2025
- Biotechnology patent applications on January 16th, 2025
- Biotechnology patent applications on January 2nd, 2025
- Blockchain patent applications on 22nd Mar 2024
- Blockchain patent applications on April 11th, 2024
- Blockchain patent applications on April 4th, 2024
- Blockchain patent applications on February 15th, 2024
- Blockchain patent applications on February 29th, 2024
- Blockchain patent applications on January 11th, 2024
- Blockchain patent applications on January 25th, 2024
- Blockchain patent applications on March 21st, 2024
- Blockchain patent applications on March 7th, 2024
- Blockchain patent applications on May 16th, 2024
D
- DNA Storage patent applications on 28th Feb 2025
- DNA Storage patent applications on February 27th, 2025
- DNA Storage patent applications on January 2nd, 2025
- Dyne Therapeutics, Inc. (20250066495). MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MUSCULAR DYSTROPHY
- Dyne Therapeutics, Inc. (20250066496). MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
F
M
T
- The regents of the university of california (20240254219). NOVEL WNT AGONIST ANTIBODIES AND THERAPEUTIC USES THEREOF simplified abstract
- The regents of the university of california (20240261334). BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD19 and CD20 simplified abstract
- The regents of the university of california (20240293463). BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD19 and CD20 simplified abstract
- The regents of the university of california (20240294657). INHIBITING ANTI-ENPP1 ANTIBODIES simplified abstract
- The regents of the university of california (20240299449). ANTI-CD72 NANOBODIES FOR IMMUNOTHERAPY simplified abstract
- The regents of the university of california (20240299545). HYBRID RECEPTORS WITH MULTIPLE TRANSCRIPTIONAL REGULATORS simplified abstract
- The regents of the university of california (20240316197). HUMAN IPSC-DERIVED MACROPHAGE simplified abstract
- The regents of the university of california (20240408137). METHODS FOR MAKING AND USING THERAPEUTIC CELLS
- The regents of the university of california (20240408204). Methods of Treating Lymphoma with a Phagocyte Having a Chimeric Antigen Receptor
- The regents of the university of california (20250000974). COMBINATION OF HUMAN NATURAL KILLER CELLS AND MACROPHAGES FOR CANCER THERAPY
- The regents of the university of california (20250002587). PREVENTION OF POSTERIOR CAPSULAR OPACIFICATION (PCO) WITH INTEGRIN AVB8 BLOCKING ANTIBODY
- The regents of the university of california (20250066469). CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES
- The regents of the university of california (20250066480). METHODS TO ENHANCE EFFICACY OF COMBINED TARGETING OF IMMUNE CHECKPOINT AND MAPK PATHWAYS
- The regents of the university of california (20250082741). Listeria Variants and Methods of Use Thereof
- The regents of the university of california (20250092129). COMPOSITIONS AND METHODS USEFUL IN PROMOTING MILK PRODUCTION
- The Regents of the University of California patent applications on August 1st, 2024
- THE REGENTS OF THE UNIVERSITY OF CALIFORNIA patent applications on August 8th, 2024
- The Regents of the University of California patent applications on December 12th, 2024
- The Regents of the University of California patent applications on February 13th, 2025
- THE REGENTS OF THE UNIVERSITY OF CALIFORNIA patent applications on February 27th, 2025
- The Regents of the University of California patent applications on January 2nd, 2025
- The Regents of the University of California patent applications on March 13th, 2025
- The Regents of the University of California patent applications on March 20th, 2025
- The Regents of the University of California patent applications on September 12th, 2024
- The Regents of the University of California patent applications on September 26th, 2024
- The Regents of the University of California patent applications on September 5th, 2024
- The Trustees of Columbia University in the City of New York (20240294643). COMPOSITIONS AND METHODS FOR MODULATING CANCER IMMUNE FITNESS simplified abstract
